Primary Immunodeficiency Therapeutics

Primary Immunodeficiency Therapeutics

Global Primary Immunodeficiency Therapeutics Market to Reach $10.4 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Primary Immunodeficiency Therapeutics estimated at US$6.7 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027. Antibody Deficiency, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$6.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellular Immunodeficiency segment is readjusted to a revised 5.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 5.9% CAGR

The Primary Immunodeficiency Therapeutics market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Innate Immune Disorders Segment to Record 6.2% CAGR

In the global Innate Immune Disorders segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$669.8 Million in the year 2020 will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 47 Featured) -

  • CSL Behring
  • Grifols International SA
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Primary Immunodeficiency Diseases – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Primary Immunodeficiency Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
TABLE 2: World Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 3: World Historic Review for Primary Immunodeficiency Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 4: World 15-Year Perspective for Primary Immunodeficiency Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
TABLE 5: World Recent Past, Current & Future Analysis for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 6: World Historic Review for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 7: World 15-Year Perspective for Antibody Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 8: World Recent Past, Current & Future Analysis for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 9: World Historic Review for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 10: World 15-Year Perspective for Cellular Immunodeficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 11: World Recent Past, Current & Future Analysis for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 12: World Historic Review for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 13: World 15-Year Perspective for Innate Immune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 14: World Recent Past, Current & Future Analysis for Immunoglobuline Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 15: World Historic Review for Immunoglobuline Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 16: World 15-Year Perspective for Immunoglobuline Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 17: World Recent Past, Current & Future Analysis for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 18: World Historic Review for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 19: World 15-Year Perspective for Antibiotic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 20: World Recent Past, Current & Future Analysis for Stem Cell & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 21: World Historic Review for Stem Cell & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 22: World 15-Year Perspective for Stem Cell & Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 23: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 24: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 25: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 27: USA Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 28: USA 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 29: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 30: USA Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 31: USA 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 33: Canada Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 34: Canada 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 35: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 36: Canada Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 37: Canada 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
JAPAN
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 39: Japan Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 40: Japan 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 41: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 42: Japan Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 43: Japan 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
CHINA
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 45: China Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 46: China 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 47: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 48: China Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 49: China 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
EUROPE
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 51: Europe Historic Review for Primary Immunodeficiency Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 52: Europe 15-Year Perspective for Primary Immunodeficiency Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 53: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 54: Europe Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 55: Europe 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 56: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 57: Europe Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 58: Europe 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
FRANCE
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 60: France Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 61: France 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 62: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 63: France Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 64: France 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
GERMANY
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 66: Germany Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 67: Germany 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 68: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 69: Germany Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 70: Germany 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 72: Italy Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 73: Italy 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 74: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 75: Italy Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 76: Italy 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
UNITED KINGDOM
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 78: UK Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 79: UK 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 80: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 81: UK Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 82: UK 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 84: Rest of Europe Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 85: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 87: Rest of Europe Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 88: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 90: Asia-Pacific Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 91: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 94: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
REST OF WORLD
TABLE 95: Rest of World Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 96: Rest of World Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 97: Rest of World 15-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2012, 2021 & 2027
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 99: Rest of World Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 100: Rest of World 15-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings